A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, citing that the company’s arguments were unconstitutional under different parts of the Constitution and that Medicare officials had not violated procedural laws. Judge Michael Shea made this decision, which was published late Wednesday, marking another legal loss for the pharmaceutical industry. Boehringer Ingelheim’s diabetes drug Jardiance was one of the first medicines selected for the negotiation program, and the company did not immediately respond to the ruling. The article is exclusive to STAT+ subscribers, providing daily intelligence on Capitol Hill and the life sciences industry.
Source link
Boehringer Ingelheim loses Medicare drug price negotiation case
